Menopause and High Cholesterol: How Estrogen Loss Affects Heart Health and Cardiovascular Risk

WHY ARE WE SO QUICK TO TREAT A WOMAN'S CHOLESTEROL BUT SO SLOW TO ADDRESS THE LOSS OF ESTROGEN THAT MAY BE CONTRIBUTING TO IT?

When a woman's cholesterol begins climbing during perimenopause or menopause, the conversation often turns immediately to medication. Yet the hormonal changes occurring in her body at the very same time may receive little attention.

Why are we treating these as two completely separate health issues?

Estrogen plays an important role in cardiovascular health. Estradiol influences how the liver processes cholesterol, how blood vessels function, and how the body distributes fat. As estrogen declines, women can experience changes in LDL cholesterol, lipoproteins, abdominal fat distribution, and vascular health that cannot be explained by aging alone.

A cholesterol panel may be showing us part of a much bigger physiological transition.

And considering that cardiovascular disease is the leading cause of death among women, shouldn't menopause be part of the cardiovascular conversation?

There is research that deserves far more attention.

Dr. Howard Hodis and Dr. Wendy Mack examined the relationship between hormone therapy, cardiovascular disease, mortality, and the timing of treatment in their published review, "Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It Is About Time and Timing."

One of the most important points they discuss is that WHEN hormone therapy begins can substantially influence its potential benefits and risks.

For years, hormone replacement therapy has often been discussed as though every woman, every formulation, and every age group carries the same risks.

But the research is more complicated than that.

A Cochrane analysis of randomized clinical trials reported that women who began hormone therapy before age 60 or within approximately 10 years of menopause experienced:

• Approximately 48% lower relative risk of coronary heart disease.

• Approximately 30% lower relative risk of death from any cause.

These findings came from subgroup analyses and should not be interpreted as a guarantee that hormone therapy prevents cardiovascular disease in every woman.

But they raise an important question about the role of timing in treatment decisions.

The ELITE trial investigated that question more directly.

Researchers found that women who started oral 17β-estradiol within six years of menopause experienced slower progression of carotid artery wall thickening, a marker of early atherosclerosis.

However, women who began treatment 10 or more years after menopause did not experience the same benefit.

The study measured changes in artery wall thickness, not actual heart attacks or mortality. Nevertheless, its findings support the possibility that the cardiovascular response to estrogen depends partly on how long a woman has been menopausal.

In other words, WHEN estrogen is introduced matters.

And waiting until a woman has been without estrogen for many years may change the potential cardiovascular effects of treatment.

Now consider another area where women frequently receive incomplete information: breast cancer risk.

The Women's Health Initiative (WHI) estrogen-alone trial followed women who had previously undergone a hysterectomy.

During long-term follow-up, women assigned to estrogen alone experienced approximately:

• 22% lower breast cancer incidence.

• 40% lower breast cancer mortality.

Those findings are important, particularly because the breast cancer risks associated with estrogen-alone therapy are not identical to those associated with combined estrogen-progestin treatment.

The WHI estrogen-alone trial used conjugated equine estrogens, and its results should not automatically be applied to every hormone formulation or every woman.

But shouldn't those findings be part of an informed discussion about breast cancer risk rather than focusing exclusively on potential harms?

None of this means cholesterol, blood pressure, ApoB, insulin resistance, diabetes risk, or family history should be ignored.

Quite the opposite.

Women deserve cardiovascular care that considers ALL of these factors, including the significant hormonal changes occurring during menopause.

Nor does it mean hormone therapy is appropriate for everyone. Current cardiovascular prevention guidelines do not recommend prescribing systemic hormone therapy solely to prevent heart disease. The decision requires individual assessment of risks, benefits, symptoms, age, timing, and treatment formulation.

But menopause should not be dismissed as a gynecological issue that has little relevance to the heart, brain, blood vessels, or metabolic health.

And hormone therapy discussions should not be limited to whether a woman's hot flashes have become unbearable.

Women deserve to understand what estrogen does throughout the body, what research has found about its decline, how treatment timing may matter, and what the evidence does and does not establish.

Treatment decisions should also involve appropriate follow-up and monitoring based on the individual patient rather than assuming that prescribing hormones alone addresses every health concern.

We should be evaluating the potential consequences of treatment AND the potential consequences of not treating menopausal symptoms and estrogen deficiency when appropriate.

Because an informed decision requires understanding both sides.

The larger question is this:

If we are going to tell women that avoiding estrogen is the safer option, shouldn't we also be prepared to discuss the research examining what happens as estrogen declines and how the timing of treatment may influence outcomes?

Women deserve more than a cholesterol prescription and a conversation about hormone therapy that ends with hot flashes.

They deserve an explanation of the whole picture.

RESEARCH REFERENCED:

Hodis HN, Mack WJ. "Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It Is About Time and Timing." The Cancer Journal, 2022.

Cochrane Database of Systematic Reviews. Hormone therapy for preventing cardiovascular disease in postmenopausal women.

ELITE Trial. "Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol." New England Journal of Medicine, 2016.

Women's Health Initiative. "Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up." JAMA, 2020.